NEW YORK, Nov. 2, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a
– New Phase 2 CALLIPER Open-Label Extension Data Support Durability of Disability Outcomes Observed During the Double-Blind Period With Continued Vidofludimus Calcium Treatment; Safety and Tolerability Profile Appeared
– Appointment Supports Immunic's Strategy to Build a Leading Multiple Sclerosis Organization Ahead of Potential Transition to Fully Integrated Commercial Company –NEW YORK, Oct. 19, 2026 /PRNewswire/ -- Immunic,
– Four Accepted Abstracts Further Characterize Investigational Vidofludimus Calcium's Profile in Multiple Sclerosis Across Long-Term Disability Outcomes, EBV-Related Immune Activity and Cognition, Novel Disability
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a
– New C-Suite Role and Appointment Underscore Commitment to Building a Strong, Commercial-Ready Data Ecosystem, in Preparation for Potential NDA Submission and Commercialization –NEW YORK, Sept. 1, 2026 /PRNewswire/ --
– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial
– Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in Relapsing Multiple Sclerosis as well as Potential
NEW YORK, July 9, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the
NEW YORK, June 10, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the
– Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis –– Additional CALLIPER Data Further Highlight Vidofludimus
– Proven Leader with Deep Multiple Sclerosis Expertise; Played Key Role in the Launch of Ocrevus® –– Will Leverage Senior Global Executive and Commercial Experience to Support Immunic's Transition Toward a
– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization –– Played Key Role in the Launch and Commercial Success of Avonex® for Multiple Sclerosis –NEW YORK, May 19, 2026 /PRNewswire/
– Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer –– Continued to Execute Phase 3 ENSURE Trials of Vidofludimus Calcium in
